IL289245B2 - PEG-conjugated cystathionine beta synthase for enzyme therapy for the treatment of homocystinuria - Google Patents
PEG-conjugated cystathionine beta synthase for enzyme therapy for the treatment of homocystinuriaInfo
- Publication number
- IL289245B2 IL289245B2 IL289245A IL28924521A IL289245B2 IL 289245 B2 IL289245 B2 IL 289245B2 IL 289245 A IL289245 A IL 289245A IL 28924521 A IL28924521 A IL 28924521A IL 289245 B2 IL289245 B2 IL 289245B2
- Authority
- IL
- Israel
- Prior art keywords
- entirety
- hereby incorporated
- see
- patients
- levels
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/43—Enzymes; Proenzymes; Derivatives thereof
- A61K38/51—Lyases (4)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/02—Inorganic compounds
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/26—Carbohydrates, e.g. sugar alcohols, amino sugars, nucleic acids, mono-, di- or oligo-saccharides; Derivatives thereof, e.g. polysorbates, sorbitan fatty acid esters or glycyrrhizin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
- A61K47/56—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule
- A61K47/59—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyureas or polyurethanes
- A61K47/60—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyureas or polyurethanes the organic macromolecular compound being a polyoxyalkylene oligomer, polymer or dendrimer, e.g. PEG, PPG, PEO or polyglycerol
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
- A61K9/19—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles lyophilised, i.e. freeze-dried, solutions or dispersions
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/08—Drugs for disorders of the alimentary tract or the digestive system for nausea, cinetosis or vertigo; Antiemetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Y—ENZYMES
- C12Y402/00—Carbon-oxygen lyases (4.2)
- C12Y402/01—Hydro-lyases (4.2.1)
- C12Y402/01022—Cystathionine beta-synthase (4.2.1.22)
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Engineering & Computer Science (AREA)
- Animal Behavior & Ethology (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Epidemiology (AREA)
- Organic Chemistry (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Biochemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Molecular Biology (AREA)
- Oil, Petroleum & Natural Gas (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Gastroenterology & Hepatology (AREA)
- General Engineering & Computer Science (AREA)
- Genetics & Genomics (AREA)
- Wood Science & Technology (AREA)
- Zoology (AREA)
- Immunology (AREA)
- Inorganic Chemistry (AREA)
- Diabetes (AREA)
- Neurology (AREA)
- Hospice & Palliative Care (AREA)
- Otolaryngology (AREA)
- Hematology (AREA)
- Ophthalmology & Optometry (AREA)
- Heart & Thoracic Surgery (AREA)
- Cardiology (AREA)
- Neurosurgery (AREA)
- Obesity (AREA)
- Biomedical Technology (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201962866810P | 2019-06-26 | 2019-06-26 | |
| US202062983860P | 2020-03-02 | 2020-03-02 | |
| PCT/US2020/039870 WO2020264333A1 (en) | 2019-06-26 | 2020-06-26 | Pegylated cystathionine beta synthase for enzyme therapy for treatment of homocystinuria |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| IL289245A IL289245A (en) | 2022-02-01 |
| IL289245B1 IL289245B1 (en) | 2025-05-01 |
| IL289245B2 true IL289245B2 (en) | 2025-09-01 |
Family
ID=71670437
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| IL289245A IL289245B2 (en) | 2019-06-26 | 2020-06-26 | PEG-conjugated cystathionine beta synthase for enzyme therapy for the treatment of homocystinuria |
Country Status (24)
| Country | Link |
|---|---|
| US (1) | US12364765B2 (https=) |
| EP (2) | EP3990005B1 (https=) |
| JP (2) | JP2022539077A (https=) |
| KR (1) | KR20220044726A (https=) |
| CN (1) | CN114786712A (https=) |
| AU (1) | AU2020302079A1 (https=) |
| BR (1) | BR112021026292A2 (https=) |
| CA (1) | CA3145426A1 (https=) |
| CL (1) | CL2021003474A1 (https=) |
| DK (1) | DK3990005T3 (https=) |
| ES (1) | ES3058596T3 (https=) |
| FI (1) | FI3990005T3 (https=) |
| HR (1) | HRP20251579T1 (https=) |
| IL (1) | IL289245B2 (https=) |
| LT (1) | LT3990005T (https=) |
| MX (2) | MX2021015966A (https=) |
| PH (1) | PH12021553235A1 (https=) |
| PL (1) | PL3990005T3 (https=) |
| PT (1) | PT3990005T (https=) |
| RS (1) | RS67521B1 (https=) |
| SA (1) | SA521431197B1 (https=) |
| SI (1) | SI3990005T1 (https=) |
| SM (1) | SMT202600042T1 (https=) |
| WO (1) | WO2020264333A1 (https=) |
Families Citing this family (6)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| FI3998067T3 (fi) | 2015-11-09 | 2024-10-31 | Univ Colorado Regents | Koostumukset ja menetelmät homokystinurian hoitoon |
| IL269544B2 (en) | 2017-04-17 | 2025-01-01 | Univ Colorado Regents | Streamlining enzyme replacement therapy for the treatment of high homocysteine |
| ES3058596T3 (en) | 2019-06-26 | 2026-03-11 | Travere Therapeutics Switzerland Gmbh | Pegylated cystathionine beta synthase for enzyme therapy for treatment of homocystinuria |
| CA3152379A1 (en) * | 2019-09-03 | 2021-03-11 | Travere Therapeutics Switzerland Gmbh | Cystathionine beta-synthase enzyme therapy for treatment of elevated homocysteine levels |
| CN115721735A (zh) * | 2022-10-13 | 2023-03-03 | 呈诺再生医学科技(北京)有限公司 | Cbs基因在制备糖尿病视网膜病变治疗药物中的应用 |
| CN120610012A (zh) * | 2023-10-20 | 2025-09-09 | T&D诊断加拿大私人有限公司 | 用于诊断个体整体健康状况的标志物以及装置 |
Citations (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2017083327A1 (en) * | 2015-11-09 | 2017-05-18 | The Regents Of The University Of Colorado, A Body Corporate | Compositions and methods for treatment of homocystinuria |
Family Cites Families (23)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US5656425A (en) | 1993-08-17 | 1997-08-12 | Regents Of The University Of Colorado | Screening for mutations by expressing cDNA segments |
| US5523225A (en) | 1993-09-13 | 1996-06-04 | Regents Of The University Of Colorado | DNA sequence encoding human cystathionine β-synthase |
| US5643575A (en) | 1993-10-27 | 1997-07-01 | Enzon, Inc. | Non-antigenic branched polymer conjugates |
| US5635375A (en) | 1995-01-09 | 1997-06-03 | Regents Of The University Of Colorado | Method of increasing the yield and heme saturation of cystathione β-synthase |
| US6653062B1 (en) | 2000-07-26 | 2003-11-25 | Wisconsin Alumni Research Foundation | Preservation and storage medium for biological materials |
| AU2003251550A1 (en) | 2002-06-17 | 2003-12-31 | The Regents Of The University Of Colorado | HUMAN CYSTATHIONINE Beta-SYNTHASE VARIANTS AND METHODS OF PRODU CTION THEREOF |
| EP1396537A1 (en) | 2002-09-04 | 2004-03-10 | Avidis SA | Treatment of elevated plasma homocysteine |
| CN1863551A (zh) | 2003-07-31 | 2006-11-15 | 抗癌公司 | 用于提高在体内的效力的PLP和PEG－rMETase的用途 |
| US20070010492A1 (en) | 2005-07-11 | 2007-01-11 | Generale Robert J | Composition and method for reducing homocysteine caused by drugs containing methyl compounds |
| BR112012004546A8 (pt) | 2009-08-29 | 2017-12-05 | Abbott Lab | Terapêutica por proteínas ligantes dll4-ligantes |
| EP2510100B1 (en) * | 2009-12-09 | 2017-10-11 | CureVac AG | Mannose-containing solution for lyophilization, transfection and/or injection of nucleic acids |
| EA201370008A1 (ru) | 2010-07-01 | 2013-06-28 | Айсис Инновэйшн Лимитид | Лечение когнитивных нарушений |
| US9034318B2 (en) | 2011-08-30 | 2015-05-19 | The Regents Of The University Of Colorado, A Body Corporate | Chemically modified cystathionine beta-synthase enzyme for treatment of homocystinuria |
| US9243239B2 (en) * | 2012-03-26 | 2016-01-26 | The Regents Of The University Of Colorado, A Body Corporate | Purification of cystathionine beta-synthase |
| US9675678B2 (en) | 2013-01-29 | 2017-06-13 | The Regents Of The University Of Colorado, A Body Corporate | Compositions and methods for treatment of homocystinuria |
| WO2015033279A1 (en) | 2013-09-04 | 2015-03-12 | Mahesh Kandula | Compositions and methods for the treatment of homocystinuria |
| CA2930665A1 (en) | 2013-11-18 | 2015-05-21 | Rubius Therapeutics, Inc. | Synthetic membrane-receiver complexes |
| MA39819A (fr) | 2014-04-01 | 2017-02-08 | Rubius Therapeutics Inc | Méthodes et compositions d'immunomodulation |
| US20180135012A1 (en) | 2015-05-13 | 2018-05-17 | Rubius Therapeutics, Inc. | Membrane-receiver complex therapeutics |
| MX2019000205A (es) | 2016-07-07 | 2019-09-23 | Rubius Therapeutics Inc | Composiciones y metodos relacionados con sistemas celulares terapeuticos que expresan arn exogeno. |
| IL269544B2 (en) | 2017-04-17 | 2025-01-01 | Univ Colorado Regents | Streamlining enzyme replacement therapy for the treatment of high homocysteine |
| ES3058596T3 (en) | 2019-06-26 | 2026-03-11 | Travere Therapeutics Switzerland Gmbh | Pegylated cystathionine beta synthase for enzyme therapy for treatment of homocystinuria |
| CA3152379A1 (en) | 2019-09-03 | 2021-03-11 | Travere Therapeutics Switzerland Gmbh | Cystathionine beta-synthase enzyme therapy for treatment of elevated homocysteine levels |
-
2020
- 2020-06-26 ES ES20743019T patent/ES3058596T3/es active Active
- 2020-06-26 CA CA3145426A patent/CA3145426A1/en active Pending
- 2020-06-26 EP EP20743019.0A patent/EP3990005B1/en active Active
- 2020-06-26 CN CN202080060487.6A patent/CN114786712A/zh active Pending
- 2020-06-26 US US17/622,112 patent/US12364765B2/en active Active
- 2020-06-26 SI SI202030699T patent/SI3990005T1/sl unknown
- 2020-06-26 AU AU2020302079A patent/AU2020302079A1/en active Pending
- 2020-06-26 BR BR112021026292A patent/BR112021026292A2/pt unknown
- 2020-06-26 FI FIEP20743019.0T patent/FI3990005T3/fi active
- 2020-06-26 HR HRP20251579TT patent/HRP20251579T1/hr unknown
- 2020-06-26 SM SM20260042T patent/SMT202600042T1/it unknown
- 2020-06-26 WO PCT/US2020/039870 patent/WO2020264333A1/en not_active Ceased
- 2020-06-26 PT PT207430190T patent/PT3990005T/pt unknown
- 2020-06-26 LT LTEPPCT/US2020/039870T patent/LT3990005T/lt unknown
- 2020-06-26 PL PL20743019.0T patent/PL3990005T3/pl unknown
- 2020-06-26 IL IL289245A patent/IL289245B2/en unknown
- 2020-06-26 EP EP25198152.8A patent/EP4663239A3/en active Pending
- 2020-06-26 PH PH1/2021/553235A patent/PH12021553235A1/en unknown
- 2020-06-26 KR KR1020227002804A patent/KR20220044726A/ko active Pending
- 2020-06-26 RS RS20251214A patent/RS67521B1/sr unknown
- 2020-06-26 DK DK20743019.0T patent/DK3990005T3/da active
- 2020-06-26 MX MX2021015966A patent/MX2021015966A/es unknown
- 2020-06-26 JP JP2021576921A patent/JP2022539077A/ja active Pending
-
2021
- 2021-12-16 MX MX2026001319A patent/MX2026001319A/es unknown
- 2021-12-23 SA SA521431197A patent/SA521431197B1/ar unknown
- 2021-12-24 CL CL2021003474A patent/CL2021003474A1/es unknown
-
2025
- 2025-06-04 JP JP2025093526A patent/JP2025143275A/ja active Pending
Patent Citations (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2017083327A1 (en) * | 2015-11-09 | 2017-05-18 | The Regents Of The University Of Colorado, A Body Corporate | Compositions and methods for treatment of homocystinuria |
Non-Patent Citations (1)
| Title |
|---|
| TOMAS, MAJTAN, ET AL., ENGINEERING AND CHARACTERIZATION OF AN ENZYME REPLACEMENT THERAPY FOR CLASSICAL HOMOCYSTINURIA, 1 May 2017 (2017-05-01) * |
Also Published As
| Publication number | Publication date |
|---|---|
| IL289245B1 (en) | 2025-05-01 |
| CA3145426A1 (en) | 2020-12-30 |
| MX2026001319A (es) | 2026-03-02 |
| SMT202600042T1 (it) | 2026-03-09 |
| CL2021003474A1 (es) | 2022-09-02 |
| HRP20251579T1 (hr) | 2026-01-30 |
| JP2022539077A (ja) | 2022-09-07 |
| RS67521B1 (sr) | 2026-01-30 |
| PL3990005T4 (pl) | 2026-03-02 |
| AU2020302079A1 (en) | 2022-02-17 |
| LT3990005T (lt) | 2026-01-12 |
| MX2021015966A (es) | 2022-04-06 |
| ES3058596T3 (en) | 2026-03-11 |
| FI3990005T3 (fi) | 2025-11-28 |
| SI3990005T1 (sl) | 2026-02-27 |
| EP4663239A2 (en) | 2025-12-17 |
| EP3990005B1 (en) | 2025-08-27 |
| BR112021026292A2 (pt) | 2022-05-31 |
| US12364765B2 (en) | 2025-07-22 |
| PT3990005T (pt) | 2025-12-17 |
| SA521431197B1 (ar) | 2024-12-03 |
| EP4663239A3 (en) | 2026-03-11 |
| DK3990005T3 (da) | 2025-12-08 |
| KR20220044726A (ko) | 2022-04-11 |
| US20220265835A1 (en) | 2022-08-25 |
| EP3990005A1 (en) | 2022-05-04 |
| IL289245A (en) | 2022-02-01 |
| JP2025143275A (ja) | 2025-10-01 |
| PL3990005T3 (pl) | 2026-03-02 |
| WO2020264333A1 (en) | 2020-12-30 |
| PH12021553235A1 (en) | 2022-08-22 |
| CN114786712A (zh) | 2022-07-22 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| US12364765B2 (en) | Pegylated cystathionine beta synthase for enzyme therapy for treatment of homocystinuria | |
| Chen et al. | Current update on retinopathy of prematurity: screening and treatment | |
| Garg | Acquired and inherited lipodystrophies | |
| IL295459A (en) | Methods of treating tuberous sclerosis complex with cannabidiol and everolimus | |
| JP2025183204A (ja) | 上昇したホモシステインレベルを処置するためのシスタチオニンベータ合成酵素による酵素療法 | |
| IL278488B2 (en) | Use of C-type natriuretic peptide variants. For the treatment of skeletal dysplasia | |
| JP2025016455A (ja) | 組換えヒト酸性アルファグリコシダーゼ | |
| IL290486B2 (en) | Subcutaneous administration of adamts13 | |
| KR20100110841A (ko) | 배합물 | |
| KR20220116305A (ko) | 신장 손상을 갖는 파브리 환자를 치료하는 방법 | |
| US20140213559A1 (en) | Compositions and treatments for dystrophies | |
| JP2023052764A (ja) | 急性虚血性脳卒中の処置のための方法及び医薬組成物 | |
| JP7009364B2 (ja) | ホモシスチン尿症の治療する組成物および方法 | |
| IL313441A (en) | Cnp therapy | |
| RU2839909C2 (ru) | Пэгилированная цистатионин-бета-синтаза для ферментотерапии для лечения гомоцистинурии | |
| HK40071277A (en) | Pegylated cystathionine beta synthase for enzyme therapy for treatment of homocystinuria | |
| HK40071277B (en) | Pegylated cystathionine beta synthase for enzyme therapy for treatment of homocystinuria | |
| RU2833879C1 (ru) | Терапия с использованием фермента цистатионин-бета-синтазы для лечения заболеваний, вызываемых повышенными уровнями гомоцистеина | |
| TWI775453B (zh) | 治療有腎損傷的法布里患者的方法 | |
| JP2022518733A (ja) | ファブリー病患者の脳血管事象のリスク低減におけるミガロスタットの使用 | |
| Cheng | Elucidating the Role of Photoreceptors in Age-Related Macular Degeneration and the Discovery of Potential Therapies | |
| EA045422B1 (ru) | Способы лечения пациентов с болезнью фабри, у которых имеется почечная недостаточность |